NCM
RNTX

Nantahala Capital Management’s Rein Therapeutics RNTX Stock Holding History

Nantahala Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-464,367
Closed -$1.64M – 151
2024
Q3 		$1.64M Hold
464,367
– – 0.08% 104
2024
Q2 		$1.29M Buy
464,367
+209,367
+82% +$860K 0.08% 101
2024
Q1 		$1.69M Buy
+255,000
New +$1.22M 0.1% 89

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Nantahala Capital Management's RNTX Position: Q4 2024 in Review

Nantahala Capital Management sold out of Rein Therapeutics (RNTX) in Q4 2024, closing a stake of 464,367 shares — an estimated $1.64M sold.

Nantahala Capital Management first reported a position in RNTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.69M in Q1 2024. 31 funds tracked by Wall St. Rank hold RNTX as of Q4 2024.

  • Nantahala Capital Management reported no remaining Rein Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 464,367 Rein Therapeutics shares in Q4 2024, an estimated $1.64M.
  • Nantahala Capital Management first reported a position in Rein Therapeutics in Q1 2024 and held it in 3 quarters.
  • Nantahala Capital Management's Rein Therapeutics position peaked at $1.69M in Q1 2024.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.